基于“三位一体”监测体系的血浆置换在心肝综合征治疗中的应用-附1例报告

吴玲 ,  谭强 ,  任丽娜 ,  甘新宇 ,  彭涛

中国输血杂志 ›› 2026, Vol. 39 ›› Issue (7) : 881 -886.

PDF (1245KB)
中国输血杂志 ›› 2026, Vol. 39 ›› Issue (7) : 881 -886. DOI: 10.13303/j.cjbt.issn.1004-549x.2026.07.010
论著

基于“三位一体”监测体系的血浆置换在心肝综合征治疗中的应用-附1例报告

作者信息 +

Application of plasma exchange based on a "trinity" monitoring system in the treatment of cardiohepatic syndrome:a case report

Author information +
文章历史 +
PDF (1274K)

摘要

目的 探讨血浆置换(PE)在心肝综合征(CHS)治疗中的技术要点及临床价值。方法 治疗1例76岁男性CHS患者,患者基础疾病包括心脏瓣膜病(二尖瓣、三尖瓣重度反流)、慢性心力衰竭(心功能Ⅳ级)合并肝功能衰竭[总胆红素(TBIL)最高590.6 μmol/L;谷丙转氨酶(ALT)最高325.4 IU/L;谷草转氨酶(AST)最高190.4 IU/L],在常规抗心衰、保肝治疗基础上效果不佳,实施3次阶梯式PE(总量6 400 mL)。治疗中建立“钙剂-液体平衡-血流动力学”三位一体监测体系,包括:1)预防性钙剂补充(PE开始前给予钙剂5 mL/h泵入);2)动态血气监测(每30-60 min监测游离钙,根据结果调整钙剂);3)个体化液体平衡设置(75%-90%);4)去甲肾上腺素备用(0.02-0.1 μg/kg/min)。结果 治疗中患者发生低钙血症(最低0.83 mmol/L)、低血压(最低65/38 mmHg)等并发症,通过调整钙剂、调节液体平衡及联用血管活性药物稳定血流动力学,治疗后B型钠尿肽(BNP)降低42.0%(7 122.53 pg/mL降至4 128.77 pg/mL),TBIL下降69.7%(590.6 μmol/L降至178.7 μmol/L),ALT下降91.8%(325.4 IU/L降至26.7 IU/L),AST下降83.2%(190.4 IU/L降至31.9 IU/L)。结论 基于“钙剂-液体平衡-血流动力学”三位一体监测体系的PE可改善CHS患者心功能及肝功能。

Abstract

Objective To investigate the technical considerations and clinical value of plasma exchange (PE) in the treatment of cardiohepatic syndrome (CHS). Methods A 76-year-old male patient with CHS was treated. The patient's underlying conditions included valvular heart disease (severe mitral and tricuspid regurgitation), chronic heart failure (cardiac function class IV) complicated with liver failure[total bilirubin (TBIL) up to 590.6 μmol/L; alanine aminotransferase (ALT) up to 325.4 IU/L; aspartate aminotransferase (AST) up to 190.4 IU/L]. Due to poor response to conventional anti-heart failure and hepatoprotective therapy, three sessions of stepwise PE (total volume 6 400 mL) were performed. A “calcium-fluid balance-hemodynamics” trinity monitoring system was established during treatment, comprising:1) prophylactic calcium supplementation (continuous calcium infusion at 5 mL/h initiated before PE); 2) dynamic blood gas monitoring (ionized calcium measured every 30-60 min with calcium dose adjusted accordingly); 3) individualized fluid balance setting (75%-90%); 4) standby norepinephrine (0.02-0.1 μg/kg/min). Results Complications such as hypocalcemia (lowest 0.83 mmol/L) and hypotension (lowest 65/38 mmHg) occurred during treatment. Hemodynamics were stabilized by adjusting calcium supplementation, regulating fluid balance, and concomitant use of vasoactive agents. After treatment, B-type natriuretic peptide (BNP) decreased by 42.0% (from 7 122.53 pg/mL to 4 128.77 pg/mL), TBIL decreased by 69.7% (from 590.6 μmol/L to 178.7 μmol/L), ALT decreased by 91.8% (from 325.4 IU/L to 26.7 IU/L), and AST decreased by 83.2% (from 190.4 IU/L to 31.9 IU/L). Conclusion PE based on the “calcium-fluid balance-hemodynamics” trinity monitoring system can improve cardiac and liver function in patients with CHS.

关键词

心肝综合征 / 血浆置换 / 胆红素 / 低钙血症 / 液体平衡 / 血流动力学

Key words

cardiohepatic syndrome / plasma exchange / bilirubin / hypocalcemia / fluid balance / hemodynamics

引用本文

引用格式 ▾
吴玲,谭强,任丽娜,甘新宇,彭涛. 基于“三位一体”监测体系的血浆置换在心肝综合征治疗中的应用-附1例报告[J]. 中国输血杂志, 2026, 39(7): 881-886 DOI:10.13303/j.cjbt.issn.1004-549x.2026.07.010

登录浏览全文

4963

注册一个新账户 忘记密码

参考文献

[1]

金书媛, 李建国. 心肝综合征的研究现状[J].中西医结合心脑血管病杂志, 2024,22(22):4135-4138.

[2]

JIN S Y, LI J G. Current status of research on cardiac-liver syndrome[J].Journal of Integrated Traditional Chinese and Western Medicine for Cardiovascular and Cerebrovascular Diseases, 2024, 22(22):4135-4138.

[3]

BRANKOVIC M, LEE P, PYRSOPOULOS N, et al. Cardiac syndromes in liver disease: A clinical conundrum[J].Journal of Clinical Translational Hepatology, 2023, 11(4):975-986.

[4]

XANTHOPOULOS A, STARLING R C, KITAI T, et al. Heart failure and liver disease:Cardiohepatic interactions[J].JACC:Heart Failure, 2019, 7(2):87-97.

[5]

中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2024年版)[J].临床肝胆病杂志, 2024, 40(12):2371-2387.

[6]

Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure (2024 version)[J].J Clinical Hepatology, 2024, 40(12):2371-2387.

[7]

TAN E X, WANG M, PANG J, et al. Plasma exchange in patients with acute and acute-on-chronic liver failure: A systematic review[J].World Journal of Gastroenterology, 2020, 26(2):219-245.

[8]

HEIDENREICH P A, BOZKURT B, AGUILAR D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure:A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines[J].Circulation, 2022, 145(18):e895-e1032.

[9]

SAMSKY M D, PATEL C B, DEWALD T A, et al. Cardiohepatic interactions in heart failure:An overview and clinical implications[J].Journal of the American College of Cardiology, 2013, 61(24):2397-2405.

[10]

LARIBI S, MEBAZAA A. Cardiohepatic syndrome:Liver injury in decompensated heart failure[J].Current Heart Failure Reports, 2014, 11(3):236-240.

[11]

MEBAZAA A, TOLPPANEN H, MUELLER C, et al. Acute heart failure and cardiogenic shock:A multidisciplinary practical guidance[J].Intensive Care Medicine, 2016, 42(2):147-163.

[12]

CHRIS-OLAIYA A, KAPOOR A, RICCI K S, et al. Therapeutic plasma exchange in liver failure[J].World Journal of Hepatology, 2021, 13(8):904-915.

[13]

KISSLING S, LEGALLAIS C, PRUIJM M, et al. A new prescription model for regional citrate anticoagulation in therapeutic plasma exchanges[J].BMC Nephrology, 2017, 18(1):81-89.

[14]

PANDEY P, SETYA D, MARIK A, et al. Single center experience of therapeutic plasma exchange in a resource-constrained setting: A study of trends in scope and complications[J].Journal of Clinical Apheresis, 2023, 38(4):463-471.

[15]

《治疗性血液成分单采技术标准》编写专家组. 治疗性血液成分单采技术标准专家共识(第2版)[J].国际输血及血液学杂志, 2020, 43(5):369-373.

[16]

The Writing Group of the Expert Consensus on Therapeutic Hemapheresis Technical Standards. Expert consensus on therapeutic hemapheresis technical standards (Second Edition)[J].Inter J Blood Transfusion and Hematology, 2020,43(5):369-373.

[17]

CONNELLY-SMITH L, ALQUIST C R, AQUINO A, et al. Guidelines on the use of therapeutic apheresis in clinical practice-Evidence-based approach from the writing committee of the American Society for Apheresis: The ninth special issue[J].Journal of Clinical Apheresis, 2023, 38(2):277-278.

[18]

HUYGH J, PEETERS Y, BERNARDS J, et al. Hemodynamic monitoring in the critically ill: an overview of current cardiac output monitoring methods[J].F1000Research, 2016, 5(F1000 Faculty Rev):2855-2865.

[19]

MAIWALL R, KULKARNI A V, ARAB J P, et al. Acute liver failure[J].Lancet, 2024, 404(10454):789-802.

[20]

REIS T, RONCO F, OSTERMANN M. Diuretics and ultrafiltration in heart failure[J].Cardiorenal Medicine, 2023, 13(1):56-65.

[21]

BEGHINI A, SAMMARTINO A M, PAPP Z, et al. 2024 update in heart failure[J].ESC Heart Failure, 2025, 12(1):8-42.

AI Summary AI Mindmap
PDF (1245KB)

0

访问

0

被引

详细

导航
相关文章

AI思维导图

/

〈 〉